A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma.

Trial Profile

A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2018

At a glance

  • Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2018 Planned primary completion date changed from 30 Apr 2018 to 30 Apr 2019.
    • 12 Dec 2017 Planned End Date changed from 1 Aug 2016 to 1 Apr 2023.
    • 12 Dec 2017 Planned primary completion date changed from 1 Aug 2016 to 30 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top